63590-64-7 Usage
Description
Terazosin is an α-1-adrenergic blocker related to prazosin, which is a medication used to treat various conditions. It is a white to off-white crystalline powder in its chemical form.
Uses
1. Hypertension Treatment:
Terazosin is used as an antihypertensive agent for the treatment of high blood pressure. It works by blocking the action of the hormone adrenaline, which causes blood vessels to narrow, thus allowing for better blood flow and reducing blood pressure.
2. Benign Prostatic Hyperplasia (BPH):
Terazosin is used as a medication for the treatment of BPH, a condition where the prostate gland becomes enlarged, causing difficulty in urinating. It helps to relax the muscles in the prostate and bladder neck, improving urine flow.
3. Once-a-Day Administration:
One of the advantages of Terazosin is its long-lasting effect, which allows it to be administered once a day. This makes it a more convenient option for patients compared to other medications that may require multiple daily doses.
4. Cardiovascular Applications:
Terazosin is used as a vasodilator in the cardiovascular industry, helping to improve blood flow and reduce the workload on the heart. This can be beneficial for patients with heart conditions or those at risk of developing cardiovascular diseases.
Clinical Use
Alpha-adrenoceptor blocker:
Hypertension
Benign prostatic hyperplasia (BPH)
Synthesis
Terazosin, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-tetrahydrofuroyl)-
piperazine (12.2.13), only differs from prazosin in that the furyl radical is replaced with a
tetrahydrofuryl radical. It is synthesized in exactly the same manner except using
1-(2-tetrahydrofuroyl)piperazine instead of 1-(2-furoyl)piperazine [48–51].
Drug interactions
Potentially hazardous interactions with other drugs
Anaesthetics: enhanced hypotensive effect.
Antidepressants: enhanced hypotensive effect with
MAOIs.
Avanafil, vardenafil, sildenafil and tadalafil: enhanced
hypotensive effect - avoid concomitant use.
Beta-blockers: enhanced hypotensive effect;
increased risk of first dose hypotensive effect.
Calcium-channel blockers: enhanced hypotensive
effect; increased risk of first dose hypotensive effect.
Diuretics: enhanced hypotensive effect; increased
risk of first dose hypotensive effect.
Moxisylyte: possibly severe postural hypotension
when used in combination.
Metabolism
Terazosin is metabolised in the liver; one of the
metabolites has antihypertensive activity.
Terazosin is excreted in faeces via the bile, and in the
urine, as unchanged drug and metabolites.
Check Digit Verification of cas no
The CAS Registry Mumber 63590-64-7 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 6,3,5,9 and 0 respectively; the second part has 2 digits, 6 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 63590-64:
(7*6)+(6*3)+(5*5)+(4*9)+(3*0)+(2*6)+(1*4)=137
137 % 10 = 7
So 63590-64-7 is a valid CAS Registry Number.
InChI:InChI=1/C19H25N5O4.ClH.2H2O/c1-26-15-10-12-13(11-16(15)27-2)21-19(22-17(12)20)24-7-5-23(6-8-24)18(25)14-4-3-9-28-14;;;/h10-11,14H,3-9H2,1-2H3,(H2,20,21,22);1H;2*1H2/p-1
63590-64-7Relevant articles and documents
A facile synthesis of [tetrahydrofuran-3H] terazosin
Egan, Judith A.,Souza, Steven M.,Filer, Crist N.
, p. 1881 - 1884 (2004)
An efficient synthesis of [3H] terazosin at high specific activity from prazosin is described.
THERAPY FOR COMPLICATIONS OF DIABETES
-
, (2009/07/02)
A method for enhancing glycemic control and/or insulin sensitivity in a human subject having diabetic nephropathy and/or metabolic syndrome comprises administering to the subject a selective endothelin A (ETA) receptor antagonist in a glycemic control and/or insulin sensitivity enhancing effective amount. A method for treating a complex of comorbidities in an elderly diabetic human subject comprises administering to the subject a selective ETA receptor antagonist in combination or as adjunctive therapy with at least one additional agent that is (i) other than a selective ETA receptor antagonist and (ii) effective in treatment of diabetes and/or at least one of said comorbidities other than hypertension. A therapeutic combination useful in such a method comprises a selective ETA receptor antagonist and at least one antidiabetic, anti-obesity or antidyslipidemic agent other than a selective ETA receptor antagonist.
Process for the preparation of terazosin hydrocloride dihydrate
-
Page/Page column 2; 3-4, (2008/06/13)
The present invention relates to an improved process for the preparation of 1-(4-amino-6,7-dimethoxyquinazolin-2-yl)-4-[[(2RS)-2,3,4,5-tetrahydrofuran-2-yl]carbonyl]piperazine hydrochloride dihydrate of Formula I, through an intermediate 1-(4-amino-6,7-dimethoxyquinazolin-2-yl)-4-[[(2RS)-2,3,4,5-tetrahydrofuran-2-yl]carbonyl]piperazine hydrochloride/hydrobromide (V).